Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPRINT: Radiation Therapy for Malignant Pleural Mesothelioma
NCT04158141Phase 3Terminated
- Sponsor
- NRG Oncology
- Start
- Jan 2020
- Primary completion
- Nov 2023
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in malignant pleural mesothelioma (MPM) (2 arms), sponsored by NRG Oncology. Primary endpoint: Overall Survival at 25 months. Started Jan 2020; status: terminated.
02
Conditions
malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT04158141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04158141.